AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for June 26, 2013 meeting (pages 3-10; Tab 1)

IV. Secretary’s report (pages 11; Tab 2)

V. Old Business
   A. HMO response to DURB follow-up questions regarding protocols (pages 13-15; Tab 3)

VI. New Business
   A. Educational newsletter for long-acting beta-agonists (pages 17-19; Tab 4)
   B. Protocols review (pages 21 - 53; Tab 5)
      1. Biologic response modifiers (pages 21-27)
      2. Dronedarone (Multaq®) (pages 28-30)
      3. Human growth hormones (pages 31-45)
      4. Palivizumab (Synagis®) (pages 46-49)
      5. Protease inhibitors for hepatitis C treatment (pages 50-53)

VII. Informational Highlights/Reports
    1. Molina Prior Authorization Report (pages 55-57; Tab 6)
    2. NJ HMO Reports 2nd Quarter 2013 (pages 58-61; Tab 6)
    3. Summary of DURB Action Items (pages 63; Tab 7)
    4. DHS and DHSS Programs Top Drugs Report (pages 65-77; Tab 8)
    5. Medication information: (pages 79-84; Tab 9)
       (a) NJ Prescription Monitoring Program
       (b) New APA guidelines on cutting antipsychotic overuse
       (c) FDA approves new DPP-4 Inhibitor alogliptin (Nesina®) for T2DM
       (d) FDA Approves dolutegravir (Tivicay®) for HIV infection